Does RIBOCICLIB Cause Second primary malignancy? 153 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 153 reports of Second primary malignancy have been filed in association with RIBOCICLIB (KISQALI). This represents 0.6% of all adverse event reports for RIBOCICLIB.
153
Reports of Second primary malignancy with RIBOCICLIB
0.6%
of all RIBOCICLIB reports
42
Deaths
70
Hospitalizations
How Dangerous Is Second primary malignancy From RIBOCICLIB?
Of the 153 reports, 42 (27.5%) resulted in death, 70 (45.8%) required hospitalization, and 28 (18.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIBOCICLIB. However, 153 reports have been filed with the FAERS database.
What Other Side Effects Does RIBOCICLIB Cause?
Neutropenia (3,585)
Nausea (3,404)
Fatigue (3,327)
Malignant neoplasm progression (2,468)
Death (2,452)
Vomiting (1,953)
Diarrhoea (1,830)
White blood cell count decreased (1,683)
Pain (1,637)
Metastases to bone (1,538)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which RIBOCICLIB Alternatives Have Lower Second primary malignancy Risk?
RIBOCICLIB vs RIBOFLAVIN
RIBOCICLIB vs RIBOFLAVIN 5'-PHOSPHATE
RIBOCICLIB vs RIBOFLAVIN 5^-PHOSPHATE
RIBOCICLIB vs RIFABUTIN
RIBOCICLIB vs RIFAMPICIN